Protara Therapeutics (NASDAQ:TARA) executives outlined progress across the company’s two clinical-stage programs during a ...

Primary endpoint met with statistically significant improvement (mean change of +2.13; p<0.001) on the Microcystic Lymphatic ...

Palvella Therapeutics, a clinical-stage biopharmaceutical company, announced the acceptance of an abstract for a poster presentation at the Society for Investigative Dermatology Annual Meeting on the ...

Shares recently traded 42% higher ahead of the morning bell at $124.89. The clinical-stage biopharmaceutical on Tuesday reported positive topline results from the its Phase 3 Selva study of Qtorin 3.9 ...

Palvella Therapeutics (NASDAQ:PVLA) shares climbed about 15% on Tuesday after the company announced positive topline data ...

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in ...

Kennedy Hubbard looks different than most 20-somethings. “We’re well aware of how she appears,” Kennedy’s mom, Leanne, said. “It’s human nature to stare. It’s just not something you see all the time.

Orbital venous-lymphatic malformations are congenital vascular malformations that infiltrate into adjacent tissues comprising of arterial, venous, and lymphatic elements. These elements have led to ...

A four-week-old, full-term male infant presented with a mass at the base of his neck (Panel A). The growth of the lesion, evident since his birth after an uncomplicated pregnancy, had been ...